Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Queen's University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Queen's University
ClinicalTrials.gov Identifier:
NCT00663650
First received: April 18, 2008
Last updated: July 11, 2011
Last verified: July 2011
  Purpose

This study is an equivalency study designed as a randomized clinical trial. Patients with a biopsy proven nodular periocular basal cell carcinoma (BCC) who have agreed to have surgical excision will be eligible. Study patients will undergo surgical excision of the lesion and then be randomized to having frozen section or permanent section pathological control. For those patients randomized to permanent section control the sample will be sent to pathology and surgical reconstruction will be performed. Patients randomized to frozen section will have additional margins re-excised before reconstruction depending on the pathologic results. Tumor clearance rates after surgical excision will be compared between the two techniques as a primary study question. Patients will be followed long-term to determine recurrence rates in the two groups. The study is designed to determine if the two techniques are equivalent within a given margin of error with respect to outcome measures.


Condition Intervention Phase
Basal Cell Carcinoma
Procedure: Permanent Section Control
Procedure: Frozen Section Control
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control

Resource links provided by NLM:


Further study details as provided by Queen's University:

Primary Outcome Measures:
  • The proportion of BCC's that are pathologically clear of tumor cells in the permanent section group compared with the frozen section group (presumably clear for all patients). [ Time Frame: 1.5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical recurrence at 3 years [ Time Frame: 4.5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 290
Study Start Date: August 2008
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Permanent Section Control
Procedure: Permanent Section Control
After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
Active Comparator: 2
Frozen Section Control
Procedure: Frozen Section Control
After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.

Detailed Description:

Basal cell carcinoma (BCC) accounts for 80-90% of skin cancers and is the most common skin cancer of the periocular region. Surgical excision is considered the gold-standard in therapy. Previous literature has shown comparable recurrence rates of BCC between surgical excision with frozen section control and surgical excision and permanent section control. To data, there are no prospective studies comparing frozen section control with permanent section control. We hypothesize that short term tumor clearance rates between frozen section and permanent section control will be similar and that long-term tumor recurrence rates will be similar between the two techniques. If we find that these two treatment options are equivalent with respect to margin control and recurrence rates, then considerable time and money savings can be accrued through using permanent section control amongst patients with periocular BCC.

The study design is a single-blind randomized controlled trial. Patients who have already agreed to surgical excision of nodular type periocular BCC will be eligible. All patients will undergo a detailed informed consent process. All patients will undergo a punch biopsy to confirm the histopathological diagnosis of BCC. The study design will be a single-blinded, randomized clinical trial. Statistically, the study will be designed as an equivalency study. Prior to randomization the BCC will be excised with 3mm clinical margins in a standard fashion. Subjects will then be randomized to one of two groups: 1. Frozen section control; 2. Permanent section control. For those patients randomized to permanent section control the clinical sample will be sent for pathologic analysis and surgical reconstruction will be performed immediately using standard oculoplastic techniques. Patients randomized to frozen section will have additional margins re-excised if necessary depending on the pathologic results. Oculoplastic reconstruction will be performed after all margins are clear. Patients will undergo examinations at the following times to assess for clinical recurrence: 1. 2 weeks and as necessary thereafter to assess surgical result and wound healing, 2. 6 months, 3. 1 year, 4. yearly up to 5 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years old or greater
  • Diagnosed with clinically nodular BCC in the periocular region confirmed by tissue biopsy
  • Agreeable and medically able to undergo surgical excision of the BCC
  • Able to give informed consent and consent has been signed
  • Able to return for all follow up visits

Exclusion Criteria:

  • BCC greater than 2cm in diameter (based on clinical examination)
  • Patient with a medical condition predisposing to multiple BCC's (ex. basal cell nevus syndrome)
  • Recurrent BCC's (i.e. a BCC that has been treated previously by surgical or other modality and has recurred will not be eligible)
  • Clinically aggressive morpheaform subtype of BCC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00663650

Contacts
Contact: Vladimir Kratky, MD, FRCSC 613-544-3400 ext 2169 kratkyv@queensu.ca

Locations
Canada, Ontario
Hotel Dieu Hospital Recruiting
Kingston, Ontario, Canada, K7L 5G2
Sponsors and Collaborators
Queen's University
Investigators
Principal Investigator: Vladimir Kratky, MD, FRCSC Department of Ophthalmology, Queen's University, Kingston, ON
  More Information

No publications provided

Responsible Party: Vladimir Kratky, MD, FRCSC, Department of Ophthalmology, Queen's University, Kingston, ON, Canada
ClinicalTrials.gov Identifier: NCT00663650     History of Changes
Other Study ID Numbers: 01
Study First Received: April 18, 2008
Last Updated: July 11, 2011
Health Authority: Canada: Canadian Institutes of Health Research

Keywords provided by Queen's University:
Basal Cell Carcinoma
BCC
Periocular BCC
Frozen Section Control
Permanent Section Control
Recurrence Rates

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Basal Cell
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on October 23, 2014